Author contributions: The author has accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: Employee of Bayer AG.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
1. Dick Sofia M, Queiroz M, Bernardi Bárbara L, Dall’Agnol A, Brondani Letícia A, Silveiro Sandra P. Update in diagnosis and management of primary aldosteronism. Clin Chem Lab Med 2018;56:360–72. Search in Google Scholar
2. Bertram Pitt LK, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013;34:2453. Search in Google Scholar
3. Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 2016;37:2105–14. Search in Google Scholar
4. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Baerfacker L, et al. Finerenone, a novel selective non-steroidal mineralocorticoid receptor antagonist with a balanced cardiorenal tissue distribution confers pronounced end organ protection at low natriuretic doses. Eu J Heart Failure 2014;16:210. Search in Google Scholar
5. Gromotowicz-Poplawska A, Szoka P, Kolodziejczyk P, Kramkowski K, Wojewodzka-Zelezniakowicz M, Chabielska E. New agents modulating the renin-angiotensin-aldosterone system – Will there be a new therapeutic option? Exp Biol Med 2016;241:1888–99. Search in Google Scholar
©2018 Walter de Gruyter GmbH, Berlin/Boston